New Collaboration to discover genes responsible for Macular Degeneration
Apr 1, 2005 - 5:01:00 PM
|
|
|
"The molecular events leading to the development of AMD are poorly understood and no pharmacological treatment has been shown to be effective in preventing, arresting or reversing the loss of vision associated with early AMD"
|
By ParAllele BioScience, South San Francisco, CA,,
[RxPG] ParAllele BioScience, Inc. announced today its joint collaboration agreement with the University of Iowa Cell Biology and Functional Genomics Laboratory, the UI Department of Ophthalmology and Visual Sciences and the UI Center for Macular Degeneration to accelerate the discovery of genes associated with age-related macular degeneration (AMD). The research initiative will be led by Gregory Hageman, Ph.D., professor at the UI Carver College of Medicine.
AMD is the leading cause of irreversible vision loss in the developed world, affecting 15 to 20 percent of individuals over the age of 60, or an estimated 50 million individuals.
"The molecular events leading to the development of AMD are poorly understood and no pharmacological treatment has been shown to be effective in preventing, arresting or reversing the loss of vision associated with early AMD," Hageman said.
Recent genome-wide linkage analyses have revealed loci on multiple chromosomes with the potential to harbor major AMD-associated genes. "We choose to collaborate with ParAllele because of their ability to comprehensively analyze those regions for both common and rare mutations that may be AMD-associated," he added. "Our long range goal is to identify new pathways and therapeutic targets that will hasten the development of pharmaceutical agents capable of delaying the onset and/or progression of AMD."
Hageman's studies are funded by the National Eye Institute at NIH and additional corporate entities.
"The agreement is an exciting opportunity for us to combine ParAllele's strengths in pharmacogenomics and high throughput gene mutation discovery with the acknowledged leadership of Dr. Hageman and his Institute in the field of AMD-associated pathways," said Nick Naclerio, CEO of ParAllele BioScience, Inc.
Advertise in this space for $10 per month.
Contact us today.
|
 |
|
Subscribe to ARMD Newsletter
|
|
|
|
Additional information about the news article
|
About ParAllele Bioscience
ParAllele BioScience, Inc. is accelerating healthcare breakthroughs by providing comprehensive genetic discovery solutions to the life science research, pharmaceutical and diagnostic sectors. The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome. The understanding of how subtle genetic variations contribute to disease risk, prognosis and drug response will lead to new and more effective drugs, predictive diagnosis, and the ability to better tailor therapies to individual patients. Headquartered in South San Francisco, California, ParAllele BioScience was founded by a team of leading researchers from the Stanford Genome Technology Center and Uppsala University. The company's investors include Abingworth Management, Index Ventures, Mohr Davidow Ventures, and Versant Ventures.
ParAllele is a trademark of ParAllele BioScience, Inc.
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
